Pegozafermin, an FGF21 analog, improved fibrosis in 22% of NASH patients in the 15 mg pegozafermin group, 26% in the 30 mg pegozafermin group, and 27% in the 44 mg pegozafermin group in a phase IIb, multicenter, double‐blind, randomized, placebo‐controlled trial.[536] The long‐acting Fc‐FGF21 fusion protein efruxifermin was demonstrated to alleviate hepatic fibrosis and resolve NASH over 24 weeks in NASH patients with moderate to severe fibrosis (NCT03976401).[537, 538]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.